How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Ataxia Market
- By Type of Ataxia: Friedreich's Ataxia, Spinocerebellar Ataxia, Ataxia Telangiectasia, Episodic Ataxia, Multiple System Atrophy
- By Treatment Type: Pharmacological Therapy, Physical Therapy, Occupational Therapy, Speech Therapy, Surgical Intervention
- By Symptom Management: Balance and Coordination Aids, Speech and Communication Devices, Mobility Assistance Devices, Nutritional Support
- By Patient Age Group: Pediatric Ataxia Patients, Adult Ataxia Patients, Geriatric Ataxia Patients
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Friedreich's Ataxia leads By Type of Ataxia at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.165 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.173 →
Full report · locked preview
Everything inside the Ataxia Market report
A complete, evidence-based study - 11 chapters and 116 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Type of Ataxia 5
Treatment Type 5
Symptom Management 4
Patient Age Group 3
Companies profiled
Biogen Inc.
Horizon Therapeutics plc
Novartis AG
Ionis Pharmaceuticals Inc.
AveXis
Inc. (a Novartis company)
PTC Therapeutics Inc.
Sangamo Therapeutics Inc.
Reata Pharmaceuticals Inc.
Sanofi S.A.
Roche Holding AG
Amgen Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Biogen Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Horizon Therapeutics plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Ionis Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →AveXis
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Inc. (a Novartis company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →PTC Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Sangamo Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Reata Pharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sanofi S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Roche Holding AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Amgen Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Pfizer Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Takeda Pharmaceutical Company Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →AbbVie Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Bristol-Myers Squibb Company
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,519M by 2033 · 9.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Friedreich's Ataxia52.2
- Spinocerebellar Ataxia7.8
- Ataxia Telangiectasia15.6
- Episodic Ataxia16.4
- Multiple System Atrophy8.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$886.5M → $1,818M · 9.4%
Europe$617.9M → $1,164M · 8.2%
Asia Pacific$564.2M → $1,191M · 9.8%
Latin America$349.2M → $700.3M · 9.1%
Middle East and Africa$268.6M → $612.3M · 10.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.372026
9.382027
9.402028
9.412029
9.422030
9.422031
9.442032
9.462033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Biogen Inc.10.4
- Horizon Therapeutics plc24.6
- Novartis AG7.1
- Ionis Pharmaceuticals Inc.12.5
- AveXis9.1
- Inc. (a Novartis company)8.4
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Type of Ataxia19.6%
Treatment Type22.8%
Symptom Management32.9%
Patient Age Group24.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.1
- Europe21.2
- Asia Pacific21.7
- Latin America12.8
- Middle East and Africa11.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Biogen Inc. | 77 | 95 | 95 | 98 | 79 | 74 | 86 |
| Horizon Therapeutics plc | 84 | 79 | 92 | 89 | 70 | 72 | 81 |
| Novartis AG | 79 | 81 | 73 | 71 | 74 | 80 | 76 |
| Ionis Pharmaceuticals Inc. | 59 | 75 | 58 | 76 | 72 | 59 | 67 |
| AveXis | 52 | 55 | 73 | 75 | 69 | 55 | 63 |
| Inc. (a Novartis company) | 52 | 50 | 53 | 59 | 61 | 53 | 55 |
| PTC Therapeutics Inc. | 40 | 59 | 57 | 60 | 57 | 46 | 53 |
| Sangamo Therapeutics Inc. | 52 | 52 | 44 | 50 | 57 | 57 | 52 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Biogen Inc.
- Horizon Therapeutics plc
- Novartis AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Biogen Inc. | ✓ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Horizon Therapeutics plc | ✓ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Novartis AG | ◐ | ✓ | ✓ | ◐ | ✓ | ◐ |
| Ionis Pharmaceuticals Inc. | ◐ | ◐ | − | ◐ | ✓ | ◐ |
| AveXis | − | − | ◐ | ◐ | ◐ | ◐ |
| Inc. (a Novartis company) | ◐ | − | − | ◐ | − | ◐ |
| PTC Therapeutics Inc. | − | ◐ | − | ◐ | ◐ | − |
| Sangamo Therapeutics Inc. | − | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Biogen Inc.86
2Horizon Therapeutics plc81
3Novartis AG76
4Ionis Pharmaceuticals Inc.67
5AveXis63
6Inc. (a Novartis company)55
7PTC Therapeutics Inc.53
8Sangamo Therapeutics Inc.52
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Biogen Inc.Horizon Therapeutics plc
Challenger2
Strong scale, closing on the leaders.
Novartis AGIonis Pharmaceuticals Inc.
Contender1
Focused players with pockets of strength.
AveXis
Niche3
Specialists in a single segment or region.
Inc. (a Novartis company)PTC Therapeutics Inc.Sangamo Therapeutics Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Type of Ataxia in North America, then scale across Ataxia Market — a $231M beachhead inside a $3.90B market.
Beachhead (SOM)$231Mobtainable near-term
Serviceable (SAM)$1.53Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Friedreich's Ataxia
Best fit — highest urgency & budget in Type of Ataxia.
Economic buyer81 fit
Spinocerebellar Ataxia
Strong fit — clear ROI and a fast path to value.
End user70 fit
Ataxia Telangiectasia
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Type of Ataxia in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Symptom Management
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel29%
Digital / self-serve21%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Type of Ataxia leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Ataxia Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified20%
Evaluation13%
Closed-won6%
$11.8KCAC
$44KLTV
3.8:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Ataxia Market is a resilient opportunity — $7.83B by 2033, compounding at 4.6%.
TAM · 2025$5.46Btoday
TAM · 2033$7.83Bforecast
CAGR4.6%2027–2033
Cumulative$59.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.83BTotal addressable market
SAM$2.97BServiceable available market
SOM$529MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.6% CAGR
Demand compounds through 2033, outpacing GDP across Type of Ataxia.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Type of Ataxia moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.83BLarge & growingTAM by 2033 at 4.6% CAGR
$2.97BServiceable nowreachable with today’s model
$529MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.11BBear3.0% CAGR
$7.83BBase4.6% CAGR
$10.0BBull6.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Ataxia Market — a $3.75B market by 2033. Plan: grow share from 7.9% to 15.3%.
Market size · 2033$3.75Btotal addressable
Market CAGR5.5%2027–2033
Target share15.3%from 7.9% today
Revenue ambition$574Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.9% | 15.3% | On track |
| Revenue | $312M | $574M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 29.8% | 41.3% | At risk |
| Customer retention | 90.2% | 93.5% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Type of Ataxia
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Treatment Type capability
A defensible second engine — invest in Treatment Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Type of Ataxia share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $70M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Type
- Authorise North America expansion plan
- Fund R&D program for Type of Ataxia leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAhead
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Ataxia Market conversation — a $8.02B market you can size, segment and defend in minutes.
Market size · 2033$8.02Btotal opportunity
Growth7.0%CAGR to 2033
Addressable buyers1,692+accounts in scope
Typical ROI5.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Type of Ataxia
Goal Grow share in Type of Ataxia
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.9×return on cost, year one
< 2 mopayback period
$76K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Biogen Inc.Horizon Therapeutics plcNovartis AGIonis Pharmaceuticals Inc.AveXisInc. (a Novartis company)PTC Therapeutics Inc.Sangamo Therapeutics Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Ataxia Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Ataxia Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →ATBS Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportAtc Communication System Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportATC Devices Market
Market size, share, segmentation and regional forecast.
$652M market · 2025 base year
View reportAtc Navigation Equipment Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportATC Run-Out Detection System Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportAtc Switching Equipment Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportAte Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportAte(Automatic Test Equipment) Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportATEX Certification Explosion-proof Collaborative Robots Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportAtherectomy And Thrombectomy Device Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportAtherectomy And Thrombectomy Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportAthermal Arrayed Waveguide Grating Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.